Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States

Clinical Therapeutics

Volumn 32, Issue 10, 2010, Pages 1756-1767

  Lee, Won Chan ^a   Conner, Christopher ^b   Hammer, Mette ^c  

^a IQVIA   (United States)

^b NOVO NORDISK INC   (United States)

^c NOVO NORDISK A S   (Denmark)

Author keywords

CORE Diabetes Model; Cost effectiveness; Exenatide; Liraglutide; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; UNITED STATES;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MODELS, ECONOMETRIC; PEPTIDES; QUALITY-ADJUSTED LIFE YEARS; STATISTICS, NONPARAMETRIC; SULFONYLUREA COMPOUNDS; UNITED STATES; VENOMS;

EID: 78650606708     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.08.010     Document Type: Article

References (59)

1. National diabetes fact sheet 2007, US Dept of Health and Human Services, Centers for Disease Control and Prevention, Accessed February 18, 2010. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf.
2. Dall TM, Zhang Y, Chen YJ, et al. The economic burden of diabetes. Health Aff (Millwood). 2010, 29:297-303.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
4. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet. 1998, 352:837-853. UK Prospective Diabetes Study Group.
5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000, 321:405-412.
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995, 28:103-117.
7. Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009, 122:443-453.
8. Lee WC, Balu S, Cobden D, et al. Prevalence and economic consequences of medication adherence in diabetes: A systemic literature review. Manag Care Interface. 2006, 19:31-41.
9. Saydah SH, Fradkin J, Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004, 291:335-342.
10. Riddle MC Oral pharmacologic management of type 2 diabetes. Am Fam Physician. 1999, 60:2613-2620.
11. Riedel AA, Heien H, Wogen J, Plauschinat CA Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 2007, 27:1102-1110.
12. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published correction appears in N Engl J Med. 2007;356:1387-1388]. N Engl J Med. 2006, 355:2427-2443. ADOPT Study Group.
13. Scarpello JH, Howlett HC Metformin therapy and clinical uses. Diab Vasc Dis Res. 2008, 5:157-167.
14. Jellinger PS, Davidson JA, Blonde L, et al. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/ AACE Diabetes Road Map Task Force. Endocr Pract. 2007, 13:260-268. ACE/ AACE Diabetes Road Map Task Force.
15. Palmer L, Conner C, Hammer M, et al. Diabetes regimen utilisation in a large managed care setting: A comparison with ADA/EASD consensus statement guidelines. Presented at: The International Society for Pharmacoeco-nomics and Outcomes Research 12th Annual European Congress 2010.
16. Brown JB, Nichols GA Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care. 2003, 9:213-217.
17. Brown JB, Nichols GA, Perry A The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004, 27:1535-1540.
18. Mitri J, Hamdy O Diabetes medications and body weight. Expert Opin Drug Safety. 2009, 8:573-584.
19. Russell-Jones D, Khan R Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab. 2007, 9:799-812.
20. Standards of medical care in diabetes-2009. Diabetes Care. 2009, 32(Suppl 1):S13-S61. American Diabetes Association.
21. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1558]. Lancet. 1998, 352:854-865. UK Prospective Diabetes Study Group.
22. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: An Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008, 31:845-851. Diabetes Outcome Progression Trial Study Group.
23. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care. 2005, 28:2543-2545.
24. Riddle MC The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002, 18(Suppl 3):S42-S49.
25. 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed noninsulin dependent diabetes followed for three years. BMJ. 1995, 14:83-88. United Kingdom Prospective Diabetes Study.
26. Gallwitz B Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol. 2005, 4:361-370.
27. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009, 32:193-203. American Diabetes Association, European Association for Study of Diabetes.
28. Byetta (exenatide) [package insert] 2008, Amylin Pharmaceuticals, Inc, San Diego, Calif.
29. Arulmozhi DK, Portha B GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci. 2006, 28:96-108.
30. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009, 374:39-47. LEAD-6 Study Group.
31. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009, 373:473-481. LEAD-3 (Mono) Study Group.
32. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 Study. Diabetes Care. 2009, 32:84-90. LEAD-2 Study Group.
33. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009, 32:1224-1230. LEAD-4 Study Investigators.
34. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008, 31:596-615. American Diabetes Association.
35. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decisionmaking. Curr Med Res Opin. 2004, 20(Suppl 1):S5-S26.
36. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004, 20(Suppl 1):S27-S40.
37. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: New results from the Framingham Study [published correction appears in Am Heart J. 2002;143:21]. Am Heart J. 2000, 139:272-281.
38. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease [published correction appears in Diabetes. 1996;45:1655]. Diabetes. 1995, 44:1249-1258. UK Prospective Diabetes Study Group.
39. Medi-Span Clinical Accessed August 10, 2010. http://www.medi-span.com.
40. Prescription Drugs 2010, US Dept of Labor, Accessed August 10, 2010. http://www.bls.gov/data/.
41. O'Brien JA, Patrick AR, Caro J Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther. 2003, 25:1017-1038.
42. DRG Guidebook: A Comprehensive Resource to the DRG Classification System 2001, St. Anthony Publishing, Reston, Va.
43. Shearer A, Scuffham P, Gordois A, Oglesby A Predicted costs and outcomes from reduced vibration detection in people with diabetes in the US. Diabetes Care. 2003, 26:2305-2310.
44. Bullano MF, Al-Zakwani IS, Fisher MD, et al. Differences in hypoglycemia event rates and associated costconsequence in patients initiated on long-acting and intermediateacting insulin products. Curr Med Res Opin. 2005, 21:291-298.
45. Drug Topics Red Book 2004, Medical Economics, Montvale, NJ.
46. Golan L, Birkmeyer JD, Welch HG The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999, 131:660-667.
47. Kantor J, Margolis DJ Treatment options for diabetic neuropathic foot ulcers: A cost-effectiveness analysis. Dermatol Surg. 2001, 27:347-351.
48. Tunis SL, Minshall ME Self-monitoring of blood glucose in type 2 diabetes: Cost-effectiveness in the United States. Am J Manag Care. 2008, 14:131-140.
49. Karter AJ, Parker MM, Moffet HH, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care. 2006, 29:1757-1763.
50. Guidelines for computer modeling of diabetes and its complications. Diabetes Care. 2004, 27:2262-2265. American Diabetes Association Consensus Panel.
51. Bagust A, Beale S Modelling Euro-Qol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005, 14:217-230.
52. Zanutto E, Conner C, Polster M, et al. Evaluation of GLP-1 Product Attributes in Treating People with Type 2 Diabetes in US: Comparing Time Trade-off and Willingness to Pay Methodologies. 2009. Poster presented at: International Society of Pharmacoeconomics and Outcomes Research 14th Annual Meeting 2009.
53. Briggs AH, Wonderling DE, Mooney CZ Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Econ. 1997, 6:327-340.
54. Lee TT, Solomon NA, Heidenreich PA, et al. Cost-effectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med. 1997, 126:337-346.
55. Salzmann P, Kerlikowske K, Phillips K Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age [published correction appears in Ann Intern Med. 1998;128:878]. Ann Intern Med. 1997, 127:955-965.
56. Mark DB, Simons TA Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Fundamentals of economic analysis. Am Heart J. 1999, 137:S38-S40.
57. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003, 6:9-17. ISPOR Task Force on Good Research Practices-Modeling Studies.
58. Ray JA, Boye KS, Yurgin N, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: A model of long-term clinical and cost outcomes. Curr Med Res Opin. 2007, 23:609-622.
59. Jendle J, Torffvit O, Ridderstråle M, et al. Willingness to pay for health improvements associated with antidiabetes treatments for people with type 2 diabetes. Curr Med Res Opin. 2010, 26:917-923.